Therefore, the objective of the present study was to assess the possible clinical relevance of serum CATB, CATL and plasma uPA, PAI-1 antigen levels in the same CRC patients, compare them with the already established serum markers CEA and CA 19-9, and to evaluate any correlation between these parameters and clinicopathological and prognostic staging of CRC. This evidence concerns the gene PLAU and colorectal carcinoma.